Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant
16 Jan 2024
Gene Therapy
Plus, news about Orion, Stalicla, Cyrano Therapeutics and Instil Bio:
Jennifer Doudna’s latest venture: Her lab published a study Thursday in Nature Biotechnology detailing how antibody fragments can be used to target virus-like particles with gene editing machinery to T cells. The fine print shows that Doudna and the study’s first author, Jenny Hamilton, co-founded Azalea Therapeutics, a genetic medicine delivery startup. Azalea has raised $10 million, according to a Forbes profile of founding scientist Connor Tsuchida. — Lei Lei Wu
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.